BODY PHARM TIRZEPATIDE GLP-1&GIP PEN(30MG TERZEPTIDE READY MIX PEN)

Terzepitide which is already approved for treating Type 2 diabetes—can lower body mass among users  by up to 15%. While semaglutide targets one molecule, glucagon-like peptide-1 (GLP-1), involved in insulin secretion, tirzepatide is the first to target two: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP).

“The historical narrative in the field has been that GIP is doing everything that GLP-1 is doing, just not as well,” Researchers have known that GLP-1 acts on cells in the pancreas and stimulates the production of insulin, which breaks down glucose in the body. It also works on the digestive system, suppressing hunger signals sent to the brain and curbing appetite. GIP has similar effects, but they’re generally not as powerful.

The scientists therefore expected to find that tirzepatide worked mainly by activating GLP-1 receptors in the body—and they questioned whether GIP would have any additional impact. Because the molecules are very similar, targeting both wouldn’t necessarily lead to an additive effect. Instead, the two entities could compete to bind to the same cell receptors, “both trying to go through the same door at the same time,

But to their surprise, the team found that tirzepatide in fact triggers a powerful GIP response. “GIP was indispensable,”In fact, in experiments on insulin-producing pancreatic cells donated from eight volunteers, the researchers found that if GIP was blocked in these cells, preventing the drug from binding to GIP receptors, the drug had no effect on stimulating insulin production. When GIP receptors were not blocked, the cells produced insulin.That was surprising to us, and the opposite of what we thought,

The reason might have something to do with differences between mice and men. Scientists rely heavily on mouse models to understand how things like GIP and GLP-1 work in living organisms, but it turns out that GIP receptors are different in human cells. While the genetic sequences for the GLP-1 receptors in mice and humans are identical, the sequences for GIP receptors in the two species are not. That’s an issue, since the most efficient way to understand how GIP works is to study human versions of the receptors in mice. “All of the data looking at tirzepatide from a mechanistic standpoint has been done mostly in mouse models,”So we thought it was important for researchers to know that there are confounding variables.”

The studies are an intriguing first step to answering questions about whether the latest class of GLP-1-based diabetes and weight-loss drugs could be more effective if combined with GIP-based medicines. More studies would be needed to explore whether targeting not just one, but several processes involved in insulin production and weight might be more effective. If that were the case, then “physicians would have different tools that give them more options to treat people,”

This study shows that for insulin secretion, which is a major biological action for glucose control, it looks like GIP is very, very important,” he says. Taking that scientific hint, Campbell hopes to build on these findings by studying GLP-1 and GIP in a larger number of human cell samples. And because the volunteers in the current trial represented a range of BMIs but did not have diabetes, he says it’s important to also include cells from people with that condition to better isolate the most efficient way to control blood sugar and weight.

Dosage

• The recommended starting dosage of Tirzepatide is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.
• After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.
• If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.
• The maximum dosage of Tirzepatide is 15 mg injected subcutaneously once weekly.
• If a dose is missed, instruct patients to administer Tirzepatide as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
• The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).

Important Administration Instructions

• Prior to initiation, train patients and caregivers on proper injection technique.
• Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL dose).
• Administer Tirzepatide once weekly, any time of day, with or without meals.
• Inject Tirzepatide subcutaneously in the abdomen, thigh, or upper arm.
• Rotate injection sites with each dose.
• Inspect Tirzepatide visually before use. It should appear clear and colorless to slightly yellow. Do not use Tirzepatide if particulate matter or discoloration is seen.
• When using Tirzepatide with insulin, administer as separate injections and never mix. It is acceptable to inject Tirzepatide and insulin in the same body region, but the injections should not be adjacent to each other.